Authors: Kakolyris, S Kouroussis, C Souglakos, J Mavroudis, D Agelaki, S Kalbakis, K Androulakis, N Vardakis, N Vamvakas, L Georgoulias, V

Citation: S. Kakolyris et al., A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors, ONCOL-BASEL, 61(4), 2001, pp. 265-270

Authors: Kalbakis, K Kouroussis, C Kakolyris, S Mavroudis, D Souglakos, J Agelaki, S Vamvakas, L Christodoulakis, M Stylianou, K Georgoulias, V

Citation: K. Kalbakis et al., Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes, BR J CANC, 85(6), 2001, pp. 798-802

Authors: Kakolyris, S Kourousis, C Koukourakis, M Androulakis, N Vamvakas, L Agelaki, S Hatzidaki, D Samonis, G Tsiftsis, D Georgoulias, V

Citation: S. Kakolyris et al., First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin, AM J CL ONC, 22(6), 1999, pp. 568-572